Reversing LRP5-Dependent Osteoporosis and SOST Deficiency–Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity

In conclusion, our data highlight the potential for novel drug targeting approaches in rare skeletal disorders ranging from severe skeletal fragility to sclerosing bone overgrowth through selective modulation of canonical WNT signaling.

These approaches should also be beneficial in the context of other medical conditions with much less severe phenotypes, such as postmenopausal osteoporosis, given the crucial role of this potent bone anabolic pathway for skeletal homeostasis

Autor: Ming‐Kang Chang, Ina Kramer, Hansjoerg Keller,…
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen